Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe.
Cancer Med
; 13(10): e7289, 2024 May.
Article
em En
| MEDLINE
| ID: mdl-38770551
ABSTRACT
BACKGROUND:
Mantle cell lymphoma (MCL) is a type of B-cell lymphoma that is currently incurable. Pirtobrutinib shows promising response rates in heavily pretreated MCL patients according to the approval study, but the real-world data are scarce.METHODS:
In this study, we retrospectively analyzed the efficacy and safety profile of pirtobrutinib in 10 relapsed/refractory MCL patients from compassionate use program (CUP).RESULTS:
On average, the patients underwent three lines of systemic therapy prior to pirtobrutinib and were predominantly BTKi exposed (9/10). The best overall response rate (BORR) was 67%. In a median follow-up of 8.6 months, the mean duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were not reached. No new safety signals were documented.CONCLUSIONS:
In summary, pirtobrutinib represented a safe and effective treatment option in a small real-world population.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfoma de Célula do Manto
/
Ensaios de Uso Compassivo
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article